Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection
We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (h...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2003-04, Vol.60 (1), p.69-73 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 73 |
|---|---|
| container_issue | 1 |
| container_start_page | 69 |
| container_title | Diabetes research and clinical practice |
| container_volume | 60 |
| creator | Fujimoto, Shimpei Matsushima, Aki Yoshitani, Kazuyasu Oya, Michihiro Shimono, Dai Takeda, Tomomi Kurose, Takeshi Yamada, Yuichiro Seino, Yutaka |
| description | We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (height 158 cm, weight 43.4 kg) was admitted to our hospital to improve glycemic control. On admission, her glycosylated hemoglobin (HbA
1c) level was 10.9% and her fasting plasma glucose (FPG) level was 332 mg/dl. After admission, her insulin regimen was altered from two injections a day using premixed insulin to four injections a day using regular insulin before each meal and NPH insulin at bedtime. Although the dosage of NPH insulin at bedtime was increased to 32 U/day, there was no improvement in the FPG level. The peak IRI value after NPH insulin injection was not observed but that after the regular insulin injection was observed. Therefore, her insulin administration regimen was changed to CSII, using regular insulin alone. Her fasting plasma glucose level decreased, glycosylated hemoglobin (HbA
1c) level improved to 7.0%, her body weight increased to 46.6 kg 4 months after starting CSII. |
| doi_str_mv | 10.1016/S0168-8227(02)00250-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73110893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822702002504</els_id><sourcerecordid>73110893</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-5c8ec2d9d324341fff7ca19432dd04fcfcabca5897e04c723308d3319255881e3</originalsourceid><addsrcrecordid>eNqFkEuLFDEQgIMo7rj6E5RcFD20Vh7dnT6JLOoKiwqu55CpVDBLP8YkPbL-ertnRvfopQqKr14fY08FvBYgmjfflmAqI2X7EuQrAFlDpe-xjTCtPJTvs80_5Iw9yvkGABql64fsTMhGdW1jNuz39e2OKsF9dFsqlPlAfR_LnPmvWH7wOOY5hIiRxsIzpXngcRjmcUrksMQ9HYg-jpx62rsSp5G7UCjxPG9xLm6kaZn1-etl9ReM4w3hCj5mD4LrMz055XP2_cP764vL6urLx08X764qVJ0oVY2GUPrOK6mVFiGEFp3otJLegw4Y0G3R1aZrCTS2UikwXinRybo2RpA6Zy-Oc3dp-jlTLnaIGZc3j8fZVgkBplMLWB9BTFPOiYLdpTi4dGsF2FW6PUi3q1EL0h6kW730PTstmLcD-buuk-UFeH4CXEbXh-RGjPmO0w2Arlfu7ZGjRcc-UrJ5NY_kY1qcWT_F_5zyB9xToRQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73110893</pqid></control><display><type>article</type><title>Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fujimoto, Shimpei ; Matsushima, Aki ; Yoshitani, Kazuyasu ; Oya, Michihiro ; Shimono, Dai ; Takeda, Tomomi ; Kurose, Takeshi ; Yamada, Yuichiro ; Seino, Yutaka</creator><creatorcontrib>Fujimoto, Shimpei ; Matsushima, Aki ; Yoshitani, Kazuyasu ; Oya, Michihiro ; Shimono, Dai ; Takeda, Tomomi ; Kurose, Takeshi ; Yamada, Yuichiro ; Seino, Yutaka</creatorcontrib><description>We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (height 158 cm, weight 43.4 kg) was admitted to our hospital to improve glycemic control. On admission, her glycosylated hemoglobin (HbA
1c) level was 10.9% and her fasting plasma glucose (FPG) level was 332 mg/dl. After admission, her insulin regimen was altered from two injections a day using premixed insulin to four injections a day using regular insulin before each meal and NPH insulin at bedtime. Although the dosage of NPH insulin at bedtime was increased to 32 U/day, there was no improvement in the FPG level. The peak IRI value after NPH insulin injection was not observed but that after the regular insulin injection was observed. Therefore, her insulin administration regimen was changed to CSII, using regular insulin alone. Her fasting plasma glucose level decreased, glycosylated hemoglobin (HbA
1c) level improved to 7.0%, her body weight increased to 46.6 kg 4 months after starting CSII.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/S0168-8227(02)00250-4</identifier><identifier>PMID: 12639768</identifier><identifier>CODEN: DRCPE9</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Abdomen ; Adult ; Biological and medical sciences ; Blood Glucose - metabolism ; Continuous subcutaneous insulin infusion ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 1 - immunology ; Drug Administration Schedule ; Female ; Glycated Hemoglobin A - metabolism ; Hematocrit ; Hormones. Endocrine system ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Immunoreactive insulin ; Injections, Subcutaneous ; Insulin Antibodies - metabolism ; Insulin, Isophane - administration & dosage ; Insulin, Isophane - therapeutic use ; Medical sciences ; NPH insulin ; Pharmacology. Drug treatments ; Time Factors ; Type-1 diabetes mellitus</subject><ispartof>Diabetes research and clinical practice, 2003-04, Vol.60 (1), p.69-73</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-5c8ec2d9d324341fff7ca19432dd04fcfcabca5897e04c723308d3319255881e3</citedby><cites>FETCH-LOGICAL-c391t-5c8ec2d9d324341fff7ca19432dd04fcfcabca5897e04c723308d3319255881e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168822702002504$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14600458$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12639768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujimoto, Shimpei</creatorcontrib><creatorcontrib>Matsushima, Aki</creatorcontrib><creatorcontrib>Yoshitani, Kazuyasu</creatorcontrib><creatorcontrib>Oya, Michihiro</creatorcontrib><creatorcontrib>Shimono, Dai</creatorcontrib><creatorcontrib>Takeda, Tomomi</creatorcontrib><creatorcontrib>Kurose, Takeshi</creatorcontrib><creatorcontrib>Yamada, Yuichiro</creatorcontrib><creatorcontrib>Seino, Yutaka</creatorcontrib><title>Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (height 158 cm, weight 43.4 kg) was admitted to our hospital to improve glycemic control. On admission, her glycosylated hemoglobin (HbA
1c) level was 10.9% and her fasting plasma glucose (FPG) level was 332 mg/dl. After admission, her insulin regimen was altered from two injections a day using premixed insulin to four injections a day using regular insulin before each meal and NPH insulin at bedtime. Although the dosage of NPH insulin at bedtime was increased to 32 U/day, there was no improvement in the FPG level. The peak IRI value after NPH insulin injection was not observed but that after the regular insulin injection was observed. Therefore, her insulin administration regimen was changed to CSII, using regular insulin alone. Her fasting plasma glucose level decreased, glycosylated hemoglobin (HbA
1c) level improved to 7.0%, her body weight increased to 46.6 kg 4 months after starting CSII.</description><subject>Abdomen</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Continuous subcutaneous insulin infusion</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 1 - immunology</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Hematocrit</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Immunoreactive insulin</subject><subject>Injections, Subcutaneous</subject><subject>Insulin Antibodies - metabolism</subject><subject>Insulin, Isophane - administration & dosage</subject><subject>Insulin, Isophane - therapeutic use</subject><subject>Medical sciences</subject><subject>NPH insulin</subject><subject>Pharmacology. Drug treatments</subject><subject>Time Factors</subject><subject>Type-1 diabetes mellitus</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuLFDEQgIMo7rj6E5RcFD20Vh7dnT6JLOoKiwqu55CpVDBLP8YkPbL-ertnRvfopQqKr14fY08FvBYgmjfflmAqI2X7EuQrAFlDpe-xjTCtPJTvs80_5Iw9yvkGABql64fsTMhGdW1jNuz39e2OKsF9dFsqlPlAfR_LnPmvWH7wOOY5hIiRxsIzpXngcRjmcUrksMQ9HYg-jpx62rsSp5G7UCjxPG9xLm6kaZn1-etl9ReM4w3hCj5mD4LrMz055XP2_cP764vL6urLx08X764qVJ0oVY2GUPrOK6mVFiGEFp3otJLegw4Y0G3R1aZrCTS2UikwXinRybo2RpA6Zy-Oc3dp-jlTLnaIGZc3j8fZVgkBplMLWB9BTFPOiYLdpTi4dGsF2FW6PUi3q1EL0h6kW730PTstmLcD-buuk-UFeH4CXEbXh-RGjPmO0w2Arlfu7ZGjRcc-UrJ5NY_kY1qcWT_F_5zyB9xToRQ</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>Fujimoto, Shimpei</creator><creator>Matsushima, Aki</creator><creator>Yoshitani, Kazuyasu</creator><creator>Oya, Michihiro</creator><creator>Shimono, Dai</creator><creator>Takeda, Tomomi</creator><creator>Kurose, Takeshi</creator><creator>Yamada, Yuichiro</creator><creator>Seino, Yutaka</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030401</creationdate><title>Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection</title><author>Fujimoto, Shimpei ; Matsushima, Aki ; Yoshitani, Kazuyasu ; Oya, Michihiro ; Shimono, Dai ; Takeda, Tomomi ; Kurose, Takeshi ; Yamada, Yuichiro ; Seino, Yutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-5c8ec2d9d324341fff7ca19432dd04fcfcabca5897e04c723308d3319255881e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Continuous subcutaneous insulin infusion</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 1 - immunology</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Hematocrit</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Immunoreactive insulin</topic><topic>Injections, Subcutaneous</topic><topic>Insulin Antibodies - metabolism</topic><topic>Insulin, Isophane - administration & dosage</topic><topic>Insulin, Isophane - therapeutic use</topic><topic>Medical sciences</topic><topic>NPH insulin</topic><topic>Pharmacology. Drug treatments</topic><topic>Time Factors</topic><topic>Type-1 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujimoto, Shimpei</creatorcontrib><creatorcontrib>Matsushima, Aki</creatorcontrib><creatorcontrib>Yoshitani, Kazuyasu</creatorcontrib><creatorcontrib>Oya, Michihiro</creatorcontrib><creatorcontrib>Shimono, Dai</creatorcontrib><creatorcontrib>Takeda, Tomomi</creatorcontrib><creatorcontrib>Kurose, Takeshi</creatorcontrib><creatorcontrib>Yamada, Yuichiro</creatorcontrib><creatorcontrib>Seino, Yutaka</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujimoto, Shimpei</au><au>Matsushima, Aki</au><au>Yoshitani, Kazuyasu</au><au>Oya, Michihiro</au><au>Shimono, Dai</au><au>Takeda, Tomomi</au><au>Kurose, Takeshi</au><au>Yamada, Yuichiro</au><au>Seino, Yutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>60</volume><issue>1</issue><spage>69</spage><epage>73</epage><pages>69-73</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><coden>DRCPE9</coden><abstract>We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (height 158 cm, weight 43.4 kg) was admitted to our hospital to improve glycemic control. On admission, her glycosylated hemoglobin (HbA
1c) level was 10.9% and her fasting plasma glucose (FPG) level was 332 mg/dl. After admission, her insulin regimen was altered from two injections a day using premixed insulin to four injections a day using regular insulin before each meal and NPH insulin at bedtime. Although the dosage of NPH insulin at bedtime was increased to 32 U/day, there was no improvement in the FPG level. The peak IRI value after NPH insulin injection was not observed but that after the regular insulin injection was observed. Therefore, her insulin administration regimen was changed to CSII, using regular insulin alone. Her fasting plasma glucose level decreased, glycosylated hemoglobin (HbA
1c) level improved to 7.0%, her body weight increased to 46.6 kg 4 months after starting CSII.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>12639768</pmid><doi>10.1016/S0168-8227(02)00250-4</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2003-04, Vol.60 (1), p.69-73 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73110893 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Abdomen Adult Biological and medical sciences Blood Glucose - metabolism Continuous subcutaneous insulin infusion Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - immunology Drug Administration Schedule Female Glycated Hemoglobin A - metabolism Hematocrit Hormones. Endocrine system Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Immunoreactive insulin Injections, Subcutaneous Insulin Antibodies - metabolism Insulin, Isophane - administration & dosage Insulin, Isophane - therapeutic use Medical sciences NPH insulin Pharmacology. Drug treatments Time Factors Type-1 diabetes mellitus |
| title | Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T20%3A11%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type-1%20diabetes%20mellitus%20with%20insufficient%20serum%20immunoreactive%20insulin%20elevation%20after%20subcutaneous%20NPH-insulin%20injection&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Fujimoto,%20Shimpei&rft.date=2003-04-01&rft.volume=60&rft.issue=1&rft.spage=69&rft.epage=73&rft.pages=69-73&rft.issn=0168-8227&rft.eissn=1872-8227&rft.coden=DRCPE9&rft_id=info:doi/10.1016/S0168-8227(02)00250-4&rft_dat=%3Cproquest_cross%3E73110893%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73110893&rft_id=info:pmid/12639768&rft_els_id=S0168822702002504&rfr_iscdi=true |